CI

At a glance

ClinicalIndex Comparison Record
Phase 3Completed· 1,029 enrolled
Drug / intervention
Ciprofloxacin +1 moredrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT00761462
NCT00761462Phase 3Completed

A Prospective, Open-label, Non-randomized, Naturalistic, Long-term Safety Surveillance, Observational Study of Either Ciprofloxacin (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) or a Non-quinolone Antibiotic (Either as Oral Suspension, Oral Tablets or Sequential IV Followed by Oral Therapy or Purely IV Therapy) in the Treatment of Pediatric Patients With Infectious Diagnoses

Bayer·interventional·Posted Sep 29, 2008·Updated Jul 31, 2015

In Brief

A Phase 3 clinical trial evaluating Ciprofloxacin and Non-quinolone antibiotic for Infectious Diseases. Completed, enrolled 1,029 participants across 67 sites in 2 countries.

Detailed Summary

Objective and subjective musculoskeletal evaluations will be performed to determine differences in the ciprofloxacin versus non-quinolone treated pediatric patients so that we can tell what the natural occurrence of such musculoskeletal conditions is in the general pediatric population.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
CountriesCanada, United States
Collaborators--

Timeline

Phase 3CompletedFinished
19992000200120022003200420052006200720082009201020112012201320142015201620172018201920202021202220232024202520262027
First PostedSep 29, 2008
Enrollment StartOct 1, 1999
Primary CompletionJan 1, 2008
TodayJul 2, 2026
Enrollment to primary: 8.3 yearsPosted 17.8 years ago

Interventions

Ciprofloxacindrug

Either as oral suspension, oral tablets or sequential intravenous (IV) - oral therapy or purely IV therapy according to label

Non-quinolone antibioticdrug

Common used dose and route